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Introduction  
Glioblastoma multiforme is the most aggressive and 
deadliest of malignant brain cancers in humans. 
Glioblastoma can grow very fast and spread quickly into 
the surrounding normal brain. This property causes 
tumor recurrence and decreases the patient survival 
rate. The current therapies including surgery, radiation 
therapy, and chemotherapy are not effective in the 
treatment of glioblastoma patients due to the tumor’s 
biological function in the brain. The median survival 
rate of patients was reported to be 15 months after 
prognosis.1 Despite the advancement of chemotherapy 
drugs for growth inhibition of cancer cells, drug entrance 
into the brain is restricted due to the blood-brain barrier 
(BBB) structure.2 To overcome this problem, studies have 
indicated that nanotechnology can help chemotherapy 
in drug delivery from BBB and increase chemotherapy 
efficacy through drug transfer to brain tumor cells. 
Recently, drug delivery carriers with targeting ligands 
have appeared to increase passage efficiency across 
BBB.3,4 However, different targeting ligands have been 
introduced for drug delivery improvement, and among 
them is 188 (Pluronic F-68) or polysorbate. Poloxamer 
188 (Pluronic F-68) can coat nanoparticles (NPs) to 
facilitate drug delivery that cannot cross BBB.5 NPs are 
synthesized from natural or synthetic polymers with a size 
of about 100 nm. NPs can deliver various drugs including 
hydrophilic and hydrophobic small drugs, vaccines, 
and biologic macromolecules.6 Among different types 
of NPs evaluated as delivery vehicles in various studies, 
poly(lactic-co-glycolic acid) (PLGA) is one of the best 
polymers due to its non-immunogenic biocompatibility 
and biodegradability. Moreover, hydrolyzed PLGA has 
low toxicity in the body.7-9 Assessing the synergistic effect 
of methotrexate (MTX) on NPs is a suitable method 
for reducing drug toxicity.10,11 In the present study, 
poloxamer188-conjugated PLGA NPs were synthesized 
to simultaneously deliver MTX and paclitaxel (PTX or 
taxol) for brain tumor treatment. PTX and MTX have 
specific solubility characteristics and various tumoricidal 
functions due to their antitumor efficiency, and thus, have 
been used to treat different brain tumors.12,13 PTX is a drug 
that inhibits cell growth, and also, is a highly hydrophobic 
drug that can cause apoptosis via disorganization of 
cyto-skeleton and inhibit the cell cycle in the late G2 
and M phases, thereby blocking cell replication.14 MTX 
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is another chemotherapy drug that can inhibit a major 
enzyme of folic acid synthesis including dihydrofolate 
reductase. MTX is able to inhibit production of purines 
and pyrimidines, contributing to growth inhibition of 
tumor cells15. The purpose of this study was to co-deliver 
two hydrophobic (PTX) and hydrophilic (MTX) drugs to 
astrocytes isolated from human glioblastoma. Moreover, 
the synergic effect of PTX and MTX-loaded NPs was 
evaluated through cytotoxicity and induced apoptosis in 
the isolated astrocytes.  
Materials and Methods
Primary Astrocytes Isolated From Human 
Glioblastoma 
Glioblastoma tissue was collected from patients under 
surgical operation whose glioblastoma was confirmed by 
a pathologist. Astrocytes were isolated from glioblastoma 
tissue through digestion with 0.05% trypsin–EDTA for 10 
minutes at 37°C water bath. Centrifugation was performed 
at 180×g for 5 minutes. Then, the astrocytes were cultured 
in DMEM/F12 medium consisting of 1% (100 U/mL) 
antibiotic/antimycotic and 2% fetal bovine serum (FBS) 
and maintained in an incubator. The FBS volume in the 
culture medium was progressively enhanced from 2% to 
10% for 2 weeks. 
MTT Assessment
The toxicity level of the drugs was evaluated through MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. The astrocytes were seeded in a 96-well 
culture plate at the density of 7×103 per well and incubated 
for 12 hours. The cells were treated with MTX, PTX, the 
MTX-PTX mixture, PTX-loaded NPs, MTX-loaded NPs, 
and PTX-MTX loaded NPs at various concentrations of 
0, 10, 20, 30, 40, and 50 µg/mL for 48 hours. An amount 
of 100 μL of DMEM containing MTT was added to each 
well into cells and incubated at 37°C for 4 hours. The 
MTT solution was eliminated from the wells, and 100 
µL of DMSO was used to dissolve formazan crystals. The 
absorbance was assessed at 570 nm using a microplate 
reader. 
Hoechst Staining
The astrocytes were cultured in DMEM/F12 medium 
containing 10% FBS overnight. Then, the astrocytes 
were treated with the drugs for 48 hours. Subsequently, 
the astrocytes were washed with phosphate buffered 
saline three times, cell fixation was performed with 4% 
paraformaldehyde, and staining was done with Hoechst 
33342 (5 μg/mL) for 20 minutes at 25°C. Finally, the cells 
were assessed using a fluorescence inverted microscope. 
Western Blot
The astrocytes (density of 1 × 106 per well) were cultured 
and treated for 48 hours. The cells were lysed and 
homogenized with RIPA lysis buffer. Protein was loaded 
in 12% SDS–polyacrylamide gel electrophoresis. Blotting 
was performed using the wet blotting system, and the 
membrane blocking was carried out in 5% non-fat milk in 
TBST for 1 hour. The membrane was treated with the rabbit 
polyclonal Bax primary antibody (1:200; cat number: sc-
493, Santa Cruz Biotechnology Inc., USA), the rabbit 
polyclonal Bcl-2 primary antibody (1:200; cat number: sc-
492, Santa Cruz Biotechnology Inc., USA), and the rabbit 
polyclonal β-actin primary antibody (1:200; cat number: 
sc-10731, Santa Cruz Biotechnology Inc., USA) overnight 
at 4°C. After washing, the membrane was incubated with 
HRP conjugated anti-goat IgG and HRP-conjugated anti-
rabbit IgG (1:10 000; cat number: sc-2004, Santa Cruz 
Biotechnology Inc., USA) for 1 hour at room temperature 
in the dark. Finally, protein was exposed on film using 
a chemiluminescence kit (Amersham Biosciences, Orsay, 
France).
Statistical Analysis
The data were presented as mean ± standard error of the 
mean. All the assessments were repeated in three separate 
experiments. The statistical analysis of the data was 
performed with SPSS 20 statistical software using one-
way analysis of variance (ANOVA) followed by Tukey’s 




The astrocytes were isolated from human glioblastoma 
tissue and treated with different drugs after 14 days (Figure 
1). MTX and PTX were the two chemotherapeutical 
drugs loaded in a similar carrier to assess the co-
delivery synergistic effect on the primary astrocytes. 
Figure 1. Astrocytes Morphology Isolated From Human 
Glioblastoma.
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The cytotoxicity level of MTX-PTX co-loaded NPs was 
compared with those of PTX-NP, MTX-NP, PTX, MTX, 
and the MTX-PTX mixture at the concentrations of 1-50 
µg/mL and the treatment time of 48 hours. The results 
indicated that the viability of cells was dependent on 
formulation and concentration of the drugs. As presented 
in Figure 2, the co-delivery of PTX and MTX significantly 
decreased the cell survival rate compared to NPs 
containing free single drug and single drug suggesting 
carrier entrance into cell and induction of the synergic 
effect. PTX-NP, MTX-NP, PTX, MTX, and the MTX-PTX 
mixture induced approximately the same toxicity in the 
primary astrocytes. Moreover, the IC50 of the co-delivery 
of PTX and MTX, PTX-NP, MTX-NP, PTX, MTX, and 
MTX-PTX mixture was 30 µg/mL for 48 hours, which 
was  also selected for the other tests of the study. 
Apoptosis Induced Into Astrocytes With Co-delivery 
of Tumoricidal Drugs
Cell programmed death was investigated using Hoechst 
staining, and the results are indicated in Figure 3 . The 
highest amount of apoptosis was observed when the 
astrocytes were exposed to PTX-MTX co-loaded NPs. 
The cell membrane was permeable to Hoechst fluorescent 
stain, and the cell nuclear was observed in red dye 
indicating apoptotic cells. However, the induced apoptosis 
level was significantly higher in the treatment groups 
of PTX-NP, MTX-NP, and the MTX-PTX mixture, as 
compared to the control. 
Western Blot Analysis
We hypothesized that the PTX-MTX co-loaded NPs 
might reduce cell survival and induce apoptosis. Thus, we 
assessed the protein expression levels of Bcl-2 and Bax. 
The results revealed that the Bcl-2 protein expression 
significantly decreased, but the Bax protein expression 
Figure 2. Survival Rate of Astrocytes. Viability of the astrocytes 
reduced with concentration increase of different drugs. *P < 0.05, 
**P < 0.01, ***P < 0.001, differences versus control. †P < 0.05, 
differences versus control.
Figure 3. Presentation of Apoptotic Astrocytes by Hoechst 
Staining.  Apoptotic cells were observed red. A) Control: cells 
are without treatment. B) Apoptotic astrocyte was treated to PTX/
MTX co-loaded nanoparticles. *P < 0.05, **P < 0.01, ***P < 0.001, 
differences versus control. (scale bar 100 μm).
Figure 4. The Proteins Expression Level of Bcl-2 and BAX in the 
Astrocytes. Apoptotic proteins rate in astrocytes treated with 
different drugs were assessed in astrocytes through western blot 
assessment. The expression level of Bcl-2 (A), and BAX (B) were 
calculated. *P < 0.05, ** P  < 0.01, *** P  < 0.001, differences 













































































































significantly increased in the astrocytes treated with PTX-
MTX co-loaded NPs, PTX-NP, MTX-NP, and the MTX-
PTX mixture, as compared to the control (Figure 4). 
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Discussion 
PTX and MTX as two chemotherapeutic drugs were 
applied in the current study. Chemotherapeutic drug 
administration is limited to mediate their side effects in 
the body. The purpose of present study was to perform 
PTX and MTX co-loading in PLGA NPs conjugated to 
poloxamer 188 to increase the drug delivery efficiency 
according to the current formulation. It is critical to 
select a good nano-carrier according to physiochemical 
characteristics of chemotherapeutic agents. Therefore, 
nano-carriers conjugated to poloxamer 188 play a major 
role in the successful pass of drugs from BBB16. Moreover, 
this nano-carrier can control drug release to increase 
bioavailability and reduce drug toxicity to normal 
tissues.17,18 Combinational therapy was selected for this 
study to mediate the synergic effect of the tumoricidal 
drugs. Therefore, a co-delivery system was considered in 
this study, which was able to simultaneously transfer the 
two drugs in a nano-carrier toward the primary astrocytes. 
In addition, PAX and MTX were co-loaded in a nano-
carrier to induce the synergic effect. Dominant reduction 
was observed in the viability of the astrocytes. NPs may 
pass across the cell membrane through endocytosis or 
phagositosis to induce the cytotoxic effect.19 Several 
tumoricidal mechanisms might be involved in the 
synergic effect. MTX appears to stop DNA replication and 
follow trigger intracellular signaling pathways consisting 
of apoptosis in astrocytes. PAX is able to inhibit assembly 
of microtubules and destroy the microtubule network in 
the cell, thereby leading to cell apoptosis.20 The results 
of this study showed apoptosis indexes including DNA 
fragmentation through Hoechst staining, downregulation 
of the anti-apoptotic protein, Bcl-2, and overexpression 
of the apoptotic protein-BAX in the primary astrocytes 
isolated from human glioblastoma.21,22
Conclusion 
In the present study, poloxamer188-conjugated PLGA 
NPs loaded with MTX and PTX were capable of co-
delivery of drugs into cells. Effects of biocompatibility, 
cytotoxicity, and apoptosis induction were observed in 
the present study. It appears to apply as a suitable carrier 
in the drug co-delivery system for brain tumor treatment. 
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